Clinical Trials

Companies initiate phase IIIb clinical trial of Tarceva in advanced NSCLC

Published in Cancer Vaccine Week, October 4th, 2004

Genentech, Inc., (DNA) and OSI Pharmaceuticals, Inc., (OSIP) announced the initiation of a phase IIIb clinical study of the investigational therapy Tarceva (erlotinib HCl) in patients with second- and third-line non-small cell lung cancer (NSCLC) who have previously received chemotherapy.

The clinical trial, called the ACT (access to care, Tarceva) trial, is a multicenter, open-label study of once-daily oral Tarceva, with endpoints of survival and response rate.

The study will enroll a patient population consistent with the pivotal Tarceva trial, which is the basis for the new drug application that was filed with the U.S. Food and Drug Administration...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Vaccine Week

Source: Cancer Vaccine Week (2004-10-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry